Aldeyra療法 ALDX 深 滬
等待開盤 12-27 09:30:00 美东时间
5.31
+0.030
+0.57%
華盛通- 最 高5.3256
- 今 開5.28
- 成交量 50.86万股
- 最 低 5.10
- 昨 收 5.28
- 總市值 3.18亿
- 52周最高 7.20
- 市盈率 靜 --
- 換手率 0.85%
- 52周最低 1.14
- 委 比 35.27%
- 總股本 5989.56万
- 歷史最高 16.70
- 量 比 0.46
- 振 幅 4.27%
- 歷史最低 1.14
- 每 手 1
- 風險率 1.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | B Riley金融大涨超53%，补交逾期第二季度报告，该季度实现扭亏为盈；Rezolve涨28%
B Riley金融大涨超53%，补交逾期第二季度报告，该季度实现扭亏为盈；Rezolve涨28%，预计年度经常性收入突破2亿美元，大幅超越此前目标>>
12-17 18:50
FDA Extends Review Timeline For Aldeyra's Dry Eye Disease Drug
FDA extends Aldeyra's reproxalap PDUFA date to March 2026 after a major NDA amendment tied to new clinical study report data.
12-16 22:25
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
12-16 20:05
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of B Riley Financial Inc (NASDAQ:RILY) rose sharply in pre-market tradin...
12-16 18:53
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
11-10 18:28
4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be rapidly gaining strength.
10-07 23:19
Alkermes appoints new CFO
Joshua Reed has been appointed as chief financial officer of Alkermes (NASDAQ:ALKS), effective September 15, 2025. Reed previously served as CFO of Omega Therapeutics and Aldeyra Therapeutics (ALDX), ...
09-12 21:08
Aldeyra Wins EMA Orphan Drug Status for ADX-2191 to Treat Rare Eye Cancer
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of
08-28 19:22
Aldeyra Therapeutics Says FDA Grants Fast Track Designation For ADX-2191 For Treatment Of Retinitis Pigmentosa
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the
08-19 19:05
